Mitotic index of invasive breast carcinoma: Achieving clinically meaningful precision and evaluating tertial cutoffs

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 11, 2009, Pages 1826-1833

  Meyer, John S ^a   Cosatto, Eric ^b   Graf, Hans Peter ^b  

^a ST LUKE S HOSPITAL   (United States)

^b NEC LABORATORIES AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINOMIAL DISTRIBUTION; BREAST CARCINOMA; CANCER GRADING; CELL COUNT; CELL HETEROGENEITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS; MITOSIS INDEX; PROBABILITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; MITOTIC INDEX; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS;

EID: 70449360025     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11(3):359-377.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, 1: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410.
3. Consensus Panel. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1998;16(2):793-795.
4. Meyer JS, Alvarez CA, Milikowski C, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18(8):1067-1078. (Pubitemid 41224497)
5. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
6. van de Vijver JM, He UD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
8. Amadori D, Nanni O, Maragolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol. 2000;18(17):3125-3134. (Pubitemid 30678737)
9. Andre F, Khalil A, Slimane K, et al. Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol. 2005;23(13):2996-3000. (Pubitemid 46224119)
10. Glass AG, Donis-Keller H, Mies C, et al. The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers. Clin Cancer Res. 2001;7(7):1843-1849. (Pubitemid 32994815)
11. Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat. 1988;12(2):191-204. (Pubitemid 19019101)
12. 3H-thymidine labelling index. Int J Cancer. 1997;74(1):122-127.
13. Goodson WH III, Moore DH II, Ljung B-M, et al. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Labeling index as a prognostic marker in breast cancer. Breast Cancer Res Treat. 2000;59(2):113-123.
14. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71(1):146-149.
15. Rudolph PMG, MacGrogan G, Bonichon F, et al. Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast: a multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999;55(1):61-71. (Pubitemid 29353975)
16. Skaland I, Janssen EAMK, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007;20(12):1307-1315. (Pubitemid 350126856)
17. Frkovic-Grazio S, Brocko M. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol. 2002;55(2):88-92. (Pubitemid 34123906)
18. Simpson JKF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion study, EST 4189. J Clin Oncol. 2000;18(10):2059-2069. (Pubitemid 30324359)
19. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-28.
20. Fidler IJ, Hart IR. The origin of metastatic heterogeneity in tumors. Eur J Cancer. 1981;17(5):487-494.
21. Meyer JS, Wittliff JL. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int J Cancer. 1991;47(2):213-220.
22. Chowdhry N, Muktha RP, Lobo FD, Kini H, Varghese R. Interobserver variation in breast cancer grading: a statistical modeling approach. Anal Quant Cytol Histol. 2006;28(4):213-218. (Pubitemid 44162597)